BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Reclassifying Achievement: Individual Accounts of Seeking after Interests - 2NASA begins fueling rocket to launch astronauts on the first lunar trip in half a century
- 3Image of foreigners being arrested in S.Africa during Eid is AI-generated
- 410 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide
- 5Craig the beer-ambassador elephant dies aged 54
- Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
- Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
- The Response Uncovered: Disentangling the Secrets of the Universe
- The most effective method to Refresh the Infotainment Framework in the Volvo XC40
- Boeing's troubled capsule won't carry astronauts on next space station flight
- Lebanese Shi’a party Amal competing, coordinating with Hezbollah, experts tell ‘Post’
- Verdicts against social media companies carry consequences. But questions linger
- Farmers call for French blockades over cow disease cull
- Inside the alleged Russian operation to trigger anti-government protests in Angola
